KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Operations: 2010-2025

Historic Cash from Operations for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to -$2.3 million.

  • Emergent BioSolutions' Cash from Operations fell 101.50% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year decrease of 92.38%. This contributed to the annual value of $58.7 million for FY2024, which is 128.45% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Cash from Operations stood at -$2.3 million, which was down 102.16% from $106.4 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Cash from Operations peaked at $328.1 million during Q4 2021, and registered a low of -$184.0 million during Q1 2023.
  • In the last 3 years, Emergent BioSolutions' Cash from Operations had a median value of -$2.3 million in 2025 and averaged -$5.0 million.
  • Per our database at Business Quant, Emergent BioSolutions' Cash from Operations plummeted by 831.37% in 2022 and then spiked by 181.08% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Cash from Operations (Quarterly) stood at $328.1 million in 2021, then crashed by 71.72% to $92.8 million in 2022, then tumbled by 65.41% to $32.1 million in 2023, then crashed by 348.91% to -$79.9 million in 2024, then crashed by 101.50% to -$2.3 million in 2025.
  • Its Cash from Operations was -$2.3 million in Q3 2025, compared to $106.4 million in Q2 2025 and -$11.2 million in Q1 2025.